US scientists have developed a novel nasal spray vaccine, GLA-3M-052-LS+OVA, demonstrating universal protection in mice against a broad spectrum of threats. Three doses effectively shielded mice from SARS-CoV-2 and other coronaviruses for three months, significantly reducing lung viral load. The vaccine also accelerated immune response to the virus and protected against bacterial infections like Staphylococcus aureus and Acinetobacter baumannii, common hospital-acquired pathogens.
Most remarkably, the vaccine reduced asthmatic responses to dust mites in vaccinated mice for three months. "We have a universal vaccine against diverse respiratory threats," stated Bali Pulendran, senior author and microbiologist at Stanford. The envisioned nasal spray could protect against viruses like COVID-19 and influenza, as well as bacterial pneumonia and spring allergens, potentially transforming medical practice.
Unlike traditional vaccines targeting specific pathogens, this new approach enhances the body's innate immune response, the first line of defense. Researchers mimicked natural signals that rally immune cells, prolonging their activity. Human trials are the next step, with potential availability within five to seven years if research progresses successfully. Experts caution that efficacy and safety in humans, and potential side effects from a hyper-alert immune system, remain key considerations.